Villarreal-Garza Cynthia, Soto-Perez-de-Celis Enrique, Sifuentes Erika, Ruano Santiago, Baez-Revueltas Berenice, Lara-Medina Fernando, Arce-Salinas Claudia, Alvarado-Miranda Alberto, Chavarri-Guerra Yanin, Caro-Sanchez Claudia, Castañeda-Soto Noel, Bargallo-Rocha Enrique, Mohar Alejandro
Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Unit of Biomedical Investigation in Cancer, National Autonomous University of Mexico and National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Breast Cancer Center, Instituto Tecnológico de Monterrey, Eugenio Garza Sada Sur 2501, Tecnológico, 64849 Monterrey, NL, Mexico.
Department of Hemato/Oncology, National Institute of Medical Science and Nutrition, Vasco de Quiroga 15, Sección XVI, Tlalpan, Ciudad de México, Distrito Federal, Mexico.
Breast. 2015 Jun;24(3):218-23. doi: 10.1016/j.breast.2015.01.011. Epub 2015 Feb 16.
Evidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.
244 patients were included. Outcomes were compared between patients who achieved pathologic complete response (pCR) (n = 119), or less than pCR (n = 125). Patients with noninvasive (ypT0/is, ypN0) residual disease were also analyzed.
119 (48.8%) patients achieved pCR. pCR was the only factor associated with improved 3 year survival (98.1% vs 92.3%: P = 0.02). Survival was better in patients with ypT0/is, ypN0 response than in those with residual invasive disease (p < 0.01). 3 year survival was 98.1% for patients with pCR and 92.6% for patients with ypTis, ypN0 response (p = 0.64).
Response rates to trastuzumab based neoadjuvant chemotherapy in Hispanics mimic that of other ethnic groups. This underlines the fact that access to treatment, rather than ethnicity, is the main prognostic factor in this population.
关于西班牙裔乳腺癌女性患者治疗结果的证据尚缺。我们分析了墨西哥接受以曲妥珠单抗为基础的新辅助化疗的HER2+疾病女性患者。
纳入244例患者。对达到病理完全缓解（pCR）的患者（n = 119）和未达到pCR的患者（n = 125）的治疗结果进行比较。还对有非侵袭性（ypT0/is，ypN0）残留疾病的患者进行了分析。
119例（48.8%）患者达到pCR。pCR是与3年生存率提高相关的唯一因素（98.1%对92.3%：P = 0.02）。ypT0/is、ypN0反应的患者生存率高于有残留侵袭性疾病的患者（p < 0.01）。pCR患者的3年生存率为98.1%，ypTis、ypN0反应的患者为92.6%（p = 0.64）。
西班牙裔患者对以曲妥珠单抗为基础的新辅助化疗的反应率与其他种族相似。这突出了一个事实，即获得治疗的机会而非种族是该人群的主要预后因素。
